Last updated: 2026/10/16
- Home
- About Us
- Research Innovation
- News
- First Show Vienna! Phase I Clinical Data of the World's First Antibody Drug SGC001 for Acute Myocardial Infarction Unveiled BIO Europe2025
- CCTV News Bulletin | Joseph Scheeren, Strategic Committee Advisor of Hotgen Biotech & Global Pharmaceutical R&D Expert, Talks About China’s Innovative Pharmaceutical Industry Development
- NMPA IND Submission! SGC001 Enters New Clinical Phase for Indicated Severe Acute Pancreatitis
- Riding the wave, The world's first acute myocardial infarction antibody SGC001 of Sungen Biomedical was presented at U.S. J.P. Morgan Conference
- Sungen Biomedical's world-first new drug SGC001 monoclonal antibody receives FDA fast track approval
- Good News! The Laboratory Animal Management Center at Sungen Biomedical is Granted
- Sungen Biomedical Was Awarded the Most Potential Seed Enterprise 2024 by EY Fudan
- Good News! The Joint Application Project of Military Medical Research Institute and Sungen Biomedical Won the First Prize
- Research Progress of SGC001, The World's First Myocardial Infarction Antibody Drug
- Focusing on the Frontier Trends: The First China Pharmaceutical Valley • Future Biological Innovative Drugs Conference
- The First China Pharmaceutical Valley • Future Biological Innovative Drugs Conference was successfully held
- Techniques for the Preparation of Human Monoclonal Antibodies
- Sungen Biomedical Won the First Prize of Beijing Science and Technology Progress Award, Demonstrating Great Scientific Research Capacity
- From Acceleration of FIC Antibodies Research by AI to Exploration of New Quality Productivity in the Biomedical Industry
- Co-operation to Create a New Chapter in the Research and Development of Biological Innovative Drugs for Cardiovascular Diseases
- The Official Opening Ceremony of the 'National Human Brain Health Project' Joint Laboratory was Held in Beijing
- Sungen Biomedical and Taizhou People's Hospital Officially Signed a Contract for Integration and Development
- An Article in Nature Reveals that the ASGR1-GP73 Axis is a Potential Therapeutic Target for Liver Injury
- 'X-Gen AI New Drug Discovery and Design Research Center' Published in PLOS Computational Biology
- Xinhua Finance: AI Enables 'China's Pharmaceutical Valley' to Accelerate the 'New' Way
- Economic Daily: 'China's Pharmaceutical Valley' Relies on AI to Innovate and Develop—Beijing Daxing Technology Enables the Biomedical Industry
- Beijing Daily: To Help Medical Treatment by the Wisdom of Science and Technology
- Professor Jie Du was Selected as One of the 'Top 2% of Global Scientists with Lifetime Scientific Impact 2024'
- Sungen Biomedical Won 2024 Top 10 Innovative Pharmaceutical Enterprises Selected by China Times
- World Heart Attack Day | BRTV, Is It True That a Single Shot Can Cure the Heart Attack?
- Make More Efforts and Focus on Innovation! The First China Pharmaceutical Valley • Future Biological Innovative Drugs Conference
- Sungen to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- The Classic Formulation of Antibody Drugs
- Three Major Forms of Antibody Therapy
- Differences Between Biological Macromolecule Drugs and Chemical Small Molecule Drugs
- Biopharmaceutical CMC Process
- Another milestone! Sungen Biomedical presented anti-tumor bispecific antibody SGT003 at the JP Morgan Healthcare Annual Conference.
- Components of Antibody Drug Conjugates
- The Role and Development Trends of Antibody Drugs
- The Mechanism of Action of Bispecific Antibody Therapy
- What Are the Types of Bispecific Antibodies?
- How AI Accelerates Antibody Discovery
- How AI is Transforming the Pharmaceutical Industry?
- Sungen Biomedical is listed on the 3rd KPMG China's Top 50 Bioinnovation Companies
- Sungen Biomedical obtained the honorary title of Model Collective of Beijing Municipality
- Opportunities and Challenges of AI-Powered Drug Development
- What Are Antibody Drugs?
- What is the Difference Between Macromolecules and Small Molecules?
- How AI Revolutionizes Drug Development
- What are Bispecific Antibodies and Their Therapeutic Potential?
- Monoclonal vs. Bispecific Antibodies
- Quality Assurance and Quality Control in Pharmaceutical Company
- AI in Antibody Discovery
- Zhongguancun FIC Alliance for Global Strategic Development of Innovative Drugs is established to help China break through the global of innovative drugs
- A major breakthrough! A phase Ib clinical study of SGC001, a “global pioneer” antibody drug for acute myocardial infarction by Sungen, has achieved positive results
- Sungen to Showcase China's Innovative Power at JPM 2026
- 2026China FIC Innovation & Collaboration Sumit
- CHINADAILY | US-China biotech summit builds bridges for innovative drug partners
- 2026 JPM Focus Series | Focusing on CTLA4 dual-target innovative platform, Sungen Released Preclinical Results of Anti-Tumor Therapeutic Bspecific Antibody SGT003 in cancer treatment for the first time
- 2026 China FIC Innovation and Collaboration Summit Held in San Francisco, Chinese Pharmaceutical Companies Showcase Innovative Achievements
- Sungen BioMed Unveils Next-Generation “SG Linker-Payload” Platform for ADC Development at 2026 J.P. Morgan Healthcare Conference
- Milestone! First Patient Dosed in Phase II Clinical Trial of SGC001 by Sungen Biomedical
- Another Global First! SGT003 Bispecific Antibody from Sungen Biomedical’s NexTreg™ Platform Accepted for IND by NMPA
- SGC001 Phase II Investigator Meeting Was Held in Beijing by Sungen Biomedical
- Sungen Biomedical’s Self-developed ADC Technology Platform Published via PCT International Application
- How an Antibody Discovery Platform De-Risks First-in-Class Drug Programs
- Developing Antibody Drugs for Cardiovascular and Cerebrovascular Diseases: Translational Challenges and Design Priorities
- Career
- Contact Us
Homepage